GSK and MMV announce start of phase III programme of tafenoquine for Plasmodium vivax malaria

GlaxoSmithKline (GSK) and Medicines for Malaria Venture (MMV) today announced the start of a phase III global programme to evaluate the efficacy and safety of tafenoquine, an investigational medicine which is being developed for the treatment and relapse prevention (radical cure) of Plasmodium vivax (P. vivax) malaria.
Source: GSK news - Category: Pharmaceuticals Source Type: news